We are live on ! Find out more
AC

Athos Capital Portfolio holdings

AUM $324M
1-Year Est. Return 16.62%
This Fund
S&P 500
This Quarter Est. Return
+10.53%
1 Year Est. Return
+16.62%
3 Year Est. Return
+82.15%
5 Year Est. Return
+203.21%
10 Year Est. Return
AUM
$66.9M
AUM Growth
-$17.2M
Cap. Flow
-$22.1M
Cap. Flow %
-33.07%
Top 10 Hldgs %
68.74%
Holding
54
New
11
Increased
1
Reduced
1
Closed
17

Top Buys

Rank Stock Value
1
SKX
Skechers
SKX
+$10.5M
2
CHA
Chagee Holdings Ltd
CHA
+$4.99M
3
TASK icon
TaskUs
TASK
+$3.05M
4
NVEE
NV5 Global
NVEE
+$2.6M
5
ZK
Zeekr
ZK
+$2.48M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 32.19%
2 Technology 20.95%
3 Consumer Staples 10.76%
4 Communication Services 9.82%
5 Healthcare 7.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMSR
51
Terrestrial Energy
IMSR
$490M
-200,000
Closed -$2.1M
ONC
52
BeOne Medicines Ltd
ONC
$32.4B
-2,114
Closed -$575K
FNA
53
DELISTED
Paragon 28, Inc.
FNA
-200,000
Closed -$2.61M
ITCI
54
DELISTED
Intra-Cellular Therapies Inc.
ITCI
-55,000
Closed -$7.26M

Similar funds

Athos Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Athos Capital held 54 positions worth $66.9M, down 20% from $84.1M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Athos Capital withdrew a net $22.1M in Q2 2025, closing 17 positions and reducing 1 holding. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $7.26M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Athos Capital opened a new position in Skechers worth $11.5M.

  • Athos Capital's largest Q2 2025 buy was Skechers: 182,588 shares worth $11.5M.
  • Athos Capital added most to Paramount Global Class B in Q2 2025, an estimated $1.76M increase.
  • Athos Capital's biggest Q2 2025 reduction was Juniper Networks, cutting an estimated $2.51M.
  • Athos Capital fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $7.26M.
  • Athos Capital's ten largest holdings make up 69% of its $66.9M portfolio in Q2 2025.
  • Athos Capital opened 11 new positions and closed 17 in Q2 2025.
  • Athos Capital's portfolio value fell 20% quarter-over-quarter to $66.9M.

Based on Athos Capital's 13F filing for Q2 2025, filed 14 Aug 2025.